Literature DB >> 29563589

Higher levels of free plasma mitochondrial DNA are associated with the onset of chronic GvHD.

Jacob Rozmus1, Sabine Ivison2, Amina Kariminia1, Vivian M Leung1, Susanna Sung1, Peter Subrt1, Stephanie J Lee3, Eric Boilard4, Irwin Walker5, Ronan Foley5, Jeff Lipton6, Geneviève Gallagher7, Stephen Couban8, Kirk R Schultz9.   

Abstract

Toll-like receptor-9 (TLR9) responsive B cells have previously been associated with the onset of extensive chronic graft-versus-host disease (cGvHD). We hypothesized that the onset of cGvHD associated with a higher level of plasma-free mitochondrial DNA (mtDNA), a putative TLR9 agonist. Plasma cell-free mtDNA levels were measured in 39 adult patients post-HSCT with and without cGvHD. mtDNA was isolated from plasma and quantified by Q-PCR amplification. We correlated B cell responsiveness to CpG-DNA, a prototypical TLR9 agonist, and previously identified cGVHD biomarkers with mtDNA levels. Free plasma mtDNA were elevated in patients post-HSCT without cGvHD compared to normal non-HSCT adults. There was a significantly higher level of free plasma mtDNA associated with the onset of cGvHD (3080 ± 1586 versus 1834 ± 1435 copies/μL; p = 0.02) compared to 6 months post-HSCT controls. Free mtDNA levels post-HSCT correlated with B cell responsiveness to CpG-DNA and known cGvHD biomarkers: CXCL10 (p = 0.003), ICAM-1 (p = 0.007), CXCL9 (p = 0.03), sCD25 (p = 0.05) and sBAFF (p = 0.05), and percentage of CD21low B cells. Plasma levels of free mtDNA are increased in cGvHD and may represent an endogenous inflammatory stimulus for TLR9 expressing B cells.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29563589     DOI: 10.1038/s41409-018-0156-y

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  4 in total

1.  Polymorphisms in CXCR3 ligands predict early CXCL9 recovery and severe chronic GVHD.

Authors:  Hao Dai; Sivaramakrishna P Rachakonda; Olaf Penack; Igor W Blau; Olga Blau; Aleksandar Radujkovic; Carsten Müller-Tidow; Peter Dreger; Rajiv Kumar; Thomas Luft
Journal:  Blood Cancer J       Date:  2021-02-27       Impact factor: 11.037

Review 2.  Recent Metabolic Advances for Preventing and Treating Acute and Chronic Graft Versus Host Disease.

Authors:  Fathima A Mohamed; Govindarajan Thangavelu; Stephanie Y Rhee; Peter T Sage; Roddy S O'Connor; Jeffrey C Rathmell; Bruce R Blazar
Journal:  Front Immunol       Date:  2021-10-12       Impact factor: 8.786

3.  Immune profile differences between chronic GVHD and late acute GVHD: results of the ABLE/PBMTC 1202 studies.

Authors:  Kirk R Schultz; Amina Kariminia; Bernard Ng; Sayeh Abdossamadi; Madeline Lauener; Eneida R Nemecek; Justin T Wahlstrom; Carrie L Kitko; Victor A Lewis; Tal Schechter; David A Jacobsohn; Andrew C Harris; Michael A Pulsipher; Henrique Bittencourt; Sung Won Choi; Emi H Caywood; Kimberly A Kasow; Monica Bhatia; Benjamin R Oshrine; Allyson Flower; Sonali Chaudhury; Donald Coulter; Joseph H Chewning; Michael Joyce; Sureyya Savasan; Anna B Pawlowska; Gail C Megason; David Mitchell; Alexandra C Cheerva; Anita Lawitschka; Shima Azadpour; Elena Ostroumov; Peter Subrt; Anat Halevy; Sara Mostafavi; Geoffrey D E Cuvelier
Journal:  Blood       Date:  2020-04-09       Impact factor: 25.476

Review 4.  Current Trends in Applications of Circulatory Microchimerism Detection in Transplantation.

Authors:  Hajnalka Andrikovics; Zoltán Őrfi; Nóra Meggyesi; András Bors; Lívia Varga; Petra Kövy; Zsófia Vilimszky; Fanni Kolics; László Gopcsa; Péter Reményi; Attila Tordai
Journal:  Int J Mol Sci       Date:  2019-09-10       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.